{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T04:36:07Z","timestamp":1726029367293},"reference-count":25,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1999,11]]},"abstract":"<jats:p>PURPOSE: This multicenter phase II trial investigated the efficacy and toxicity of a combination of the novel intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl (DPPE), and doxorubicin in patients with anthracycline-na\u00efve metastatic breast cancer. Preclinical models and early single institutional studies suggested DPPE could potentiate the cytotoxicity of doxorubicin.<\/jats:p><jats:p>PATIENTS AND METHODS: Forty-two women, 32 to 77 years old (median, 59 years), with anthracycline-na\u00efve metastatic breast cancer were treated. Patients may have had one previous regimen of nonanthracycline chemotherapy, either in the adjuvant or metastatic disease treatment setting. DPPE (6 mg\/kg) was administered as an 80 minute intravenous infusion with doxorubicin (60 mg\/m<jats:sup>2<\/jats:sup>) given intravenously over the last 20 minutes of the DPPE infusion. Patients were premedicated with an antiemetic and sedating regimen. The DPPE\/doxorubicin treatment was given every 21 days for a maximum of seven cycles.<\/jats:p><jats:p>RESULTS: All 42 patients were assessable. Overall, toxicity was comparable to that expected with doxorubicin alone, with the exception of DPPE-related motion sickness, mild hallucinations, and cerebellar signs at the time of the infusion. These CNS side effects were manageable in an ambulatory care setting, improved with subsequent cycles of treatment, and did not usually require hospitalization. Four patients developed febrile neutropenia. Thirty-five patients received four or more cycles of chemotherapy. The overall response rate was 52.5% (95% confidence interval, 36% to 68%), with 9.5% complete responses (n = 4), 43% partial responses (n = 18), and 38% of patients with stable disease (n = 16).<\/jats:p><jats:p>CONCLUSION: The antitumour effects of DPPE\/doxorubicin the 52.5% response rate seems encouraging, particularly in consideration of the fact that a recently reported randomized National Cancer Institute of Canada Clinical Trials Group trial using single-agent doxorubicin 60 mg\/m<jats:sup>2<\/jats:sup>in one of the treatment arms achieved a 31% response rate. Thus, a randomized phase III trial of doxorubicin versus doxorubicin plus DPPE is being conducted in this clinical setting.<\/jats:p>","DOI":"10.1200\/jco.1999.17.11.3431","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:06:07Z","timestamp":1487916367000},"page":"3431-3437","source":"Crossref","is-referenced-by-count":14,"title":["Phase II Trial of N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and Doxorubicin Chemotherapy in Metastatic Breast Cancer: A National Cancer Institute of Canada Clinical Trials Group Study"],"prefix":"10.1200","volume":"17","author":[{"given":"K.","family":"Khoo","sequence":"first","affiliation":[{"name":"From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Brandes","sequence":"additional","affiliation":[{"name":"From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Reyno","sequence":"additional","affiliation":[{"name":"From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Arnold","sequence":"additional","affiliation":[{"name":"From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Dent","sequence":"additional","affiliation":[{"name":"From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Vandenberg","sequence":"additional","affiliation":[{"name":"From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Fisher","sequence":"additional","affiliation":[{"name":"From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Eisenhauer","sequence":"additional","affiliation":[{"name":"From The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, ON; Manitoba Cancer Treatment and Research Foundation, Winnipeg, MB; Hamilton Regional Cancer Center, Hamilton, ON; Northwestern Ontario Regional Cancer Center, Thunder Bay, ON; and London Regional Cancer Center, London, ON, Canada; and Bristol-Myers Squibb, Wallingford, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-3431","doi-asserted-by":"crossref","unstructured":"Kahlson G, Rosengren E, Steinhardt C: Histamine-forming capacity of multiplying cells. J Physiol 151:131,1960-138,","DOI":"10.1113\/jphysiol.1960.sp006427"},{"key":"R3-3431","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(84)90289-4"},{"key":"R4-3431","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(90)90341-H"},{"key":"R5-3431","doi-asserted-by":"crossref","unstructured":"Brandes LJ, Davie JR, Paraskevas F, et al: The antiproliferative potency of histamine antagonists correlates with inhibition of binding of H-histamine to novel intracellular histamine receptors (H) in microsomal and nuclear fractions of rat liver. Agents Actions 33:325,1991-342, (suppl)3ic","DOI":"10.1007\/978-3-0348-7309-3_24"},{"key":"R6-3431","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.18.1329"},{"key":"R7-3431","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4644(19980601)69:3<233::AID-JCB1>3.0.CO;2-S"},{"key":"R8-3431","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(92)91801-V"},{"key":"R10-3431","doi-asserted-by":"publisher","DOI":"10.1139\/y88-187"},{"key":"R11-3431","doi-asserted-by":"publisher","DOI":"10.1159\/000200489"},{"key":"R12-3431","unstructured":"Menendez AT, Raventos-Suarez C, Fairchild C, et al: Mechanism of action of DPPE, a chemosensitizing agent. Proc Am Assoc Cancer Res 36:509,1998, (abstr A3462)"},{"key":"R13-3431","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(96)00345-0"},{"key":"R14-3431","unstructured":"McClay E, Albright K, Jones J, et al: N, N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine.HCl (DPPE) is synergistic with cisplatin (DDP) in human melanoma cell lines. Proc Annu Meet Am Assoc Cancer Res 34:402,1993, (abstr 2398)"},{"key":"R15-3431","unstructured":"Jones J, Albright K, Christen R, et al: Synergy between tamoxifen and cisplatin in human melanoma cells is dependent on the presence of antiestrogen-binding sites. Cancer Research 57:2657,1997-2660,"},{"key":"R16-3431","unstructured":"Brandes LJ, McDonald KA, Bracken SP, et al: Results of a pilot study testing the hypothesis that the intracellular histamine antagonist, DPPE increases the therapeutic index of doxorubicin. Adv Bio Sci 89:375,1993-401,"},{"key":"R17-3431","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1281"},{"key":"R18-3431","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.6.1398"},{"key":"R19-3431","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005909808529"},{"key":"R20-3431","doi-asserted-by":"publisher","DOI":"10.2307\/2530297"},{"key":"R21-3431","unstructured":"Norris B, Pritchard K, James K, et al: A phase III comparative study of vinorelbine combined with doxorubicin vs doxorubicin alone in metastatic breast cancer: A National Cancer Institute of Canada (NCIC CTG) study. Proc Am Soc Clin Oncol 15:98,1996, (abstr 59)"},{"key":"R22-3431","unstructured":"Warrington RC, Fang WD, Zhang LU: L-histidinol reverses resistance to cisplatinum and other antineoplastics in a tumourigenic epithelial cell line. Anticancer Res 16:3641,1997-3646,"},{"key":"R23-3431","unstructured":"Warrington RC, Cheng I, Fang WD: Susceptibility of human colon carcinoma cells to anticancer drugs is enhanced by L-histidinol. Anticancer Res 14:367,1994-372,"},{"key":"R24-3431","unstructured":"Warrington RC, Cheng I, Zhang L, et al: L-histidinol increases the vulnerability of cultured human leukemia and lymphoma cells to anticancer drugs. Anticancer Res 13:2107,1993-2112,"},{"key":"R25-3431","doi-asserted-by":"publisher","DOI":"10.1139\/o92-056"},{"key":"R26-3431","unstructured":"Warrington RC, Fang WD, Zhang L, et al: Mimetics of L-histidinol which selectively modulate daunomycin toxicity in normal and tumorigenic epithelial cells. Anticancer Res 16:3635,1996-3639,"},{"key":"R27-3431","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/81.4.298"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1999.17.11.3431","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T17:15:38Z","timestamp":1719076538000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1999.17.11.3431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1999,11]]}},"alternative-id":["10.1200\/JCO.1999.17.11.3431"],"URL":"https:\/\/doi.org\/10.1200\/jco.1999.17.11.3431","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,11]]}}}